‘Multiple Sclerosis market to reach more than $18bn by 2018′.
Currently valued at $12bn, the multiple sclerosis market is expected to peak at $18.3bn in 2018, driven by the continued uptake of novel oral therapies, according to research conducted by Datamonitor Healthcare.
Research from Datamonitor Healthcare, the leading independent healthcare analyst, has revealed that the multiple sclerosis market in the US, Japan and five major EU markets is estimated to expand by over $6bn at a compound annual growth rate of 7.4%, peaking at $18.3bn in 2018.
This increase will largely be due to the emergence of novel oral therapies, including Gilenya, Aubagio and Tecfidera, which are predicted to grow at an annual rate of 20.9% until 2021.
Daniel Chancellor, lead analyst at Datamonitor Healthcare said: “Although injectable therapies possessed 88% of the market in 2012, there is now a much higher demand for oral therapies among multiple sclerosis patients.
“We are expecting Biogen Idec’s Tecfidera to become the dominant multiple sclerosis therapy and we have forecast the drug to secure annual revenues of $4.5bn 2021, equating to a 26% market share. This would be comparable to Copaxone’s current standing, which is impressive considering the increased level of competition expected in the future multiple sclerosis market.”
About Datamonitor Healthcare…
Datamonitor Healthcare is the leading independent source of expert research across key pharmaceutical and biotechnology sectors. Our event-sensitive analysis evolves alongside the market to provide the most timely and representative market insight, supported by robust sources and methodologies that validate forecasts and assumptions. Rely on our global team of expert analysts, journalists and thought leaders to help you monitor and respond to spontaneous and disruptive industry developments.
For more information on this research, please Contact Us